ZLD Share Price History
22 Jul, 2020
Zelira Therapeutics Enters Agreement with Cardiovascular Solutions of Central Mississippi to Develop Products
Zelira Therapeutics Ltd (ASX: ZLD) (OTCQB: ZLDAF), a global leader in the development of clinically validated cannabis medicines, is pleased to announce it has entered into a binding agreement with US-based Cardiovascular Solutions of Central Mississippi to develop products that target symptoms and health risks related to cardiovascular disease and diabetes. According to the Agreement, Zelira will develop exclusively for CVSCM novel, hemp-derived formulations of CBD and other cannabinoids to address a range of therapeutic needs associated with Peripheral Arterial Disease (PAD) and Diabetic Neuropathies (DPN).
08 May, 2020
Those Who Purchased Zelira Therapeutics (ASX:ZLD) Shares Three Years Ago Have A 48% Loss To Show For It
As an investor its worth striving to ensure your overall portfolio beats the market average. But its virtually certain...
08 Apr, 2020
Zelira Therapeutics Completes World's First Clinical Trials for Treatment of Insomnia with Medical Cannabis
Zelira Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF), a global leader in the development of clinically validated cannabis medicines based in both Perth, Australia and Philadelphia, is pleased to announce it has received the final report for its ZTL-101 medicinal cannabis trial for insomnia. Its findings represent a world-first clinical validation demonstrating that ZTL-101 cannabis treatment is safe and effective for chronic insomnia. These results open prospects to launch and distribute this product in global markets including the USA in the second half of 2020.
19 Feb, 2020
Teleconference 11am (AEDT) today with
28 Jan, 2020
Zelira Therapeutics Limited (ASX: ZLD, OTCQB: ZLDAF) is pleased to announce a collaboration with the Parkinson's Foundation, one of the United States of America's leading communities for people living with Parkinson's disease (PD), to gather insights from people with PD about their understanding of and use of medical cannabis and hemp-derived therapies. In 2019, Zelira Therapeutics participated in the Medical Cannabis Conference organized by the Parkinson's Foundation, and is now assisting in the development of a survey to understand the current use and perceived benefits of medical cannabis among people with PD. This collaboration combines the Foundation's understanding of the underlying science of Parkinson's disease and the most prevalent symptoms impacting people with the disease with Zelira Therapeutics' extensive experience in pharmaceutical and condition-specific medical cannabis product development.
03 Dec, 2019
Zelira Therapeutics Ltd (ASX: ZLD, OTCQB: ZLDAF, Zelira), formerly Zelda Therapeutics Ltd, announced today it will bring its HOPE® Franchise to the state of Louisiana with a licensing agreement that will generate immediate revenue through a licensing arrangement which includes an up-front fee and ongoing royalties. The commercial terms of this arrangement remain confidential. The Franchise was launched successfully in Pennsylvania in May 2019 under Ilera Healthcare which holds the license for the state. Since entering the market, HOPE® has shown strong revenue growth establishing itself as the top selling formulated medicinal cannabis product line in Pennsylvania.
05 Nov, 2019
Can We See Significant Insider Ownership On The Zelda Therapeutics Limited (ASX:ZLD) Share Register?
A look at the shareholders of Zelda Therapeutics Limited (ASX:ZLD) can tell us which group is most powerful. Large...